TISIDB

Summary
Symbol	SDC1
Name	syndecan 1
Aliases	CD138; syndecan; SYND1; syndecan proteoglycan 1; SDC; CD138 antigen; heparan sulfate proteoglycan fibroblast ......
Chromosomal Location	2p24.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway

> Subcellular Location, Domain and Function [ TOP ]
Subcellular Location	Membrane Single-pass type I membrane protein Secreted Secreted, exosome Note=Shedding of the ectodomain produces a soluble form.
Domain	PF01034 Syndecan domain
Function	Cell surface proteoglycan that bears both heparan sulfate and chondroitin sulfate and that links the cytoskeleton to the interstitial matrix. Regulates exosome biogenesis in concert with SDCBP and PDCD6IP (PubMed:22660413).

> Gene Ontology [ TOP ]
Biological Process	GO:0000302 response to reactive oxygen species GO:0001523 retinoid metabolic process GO:0001655 urogenital system development GO:0001657 ureteric bud development GO:0001822 kidney development GO:0001823 mesonephros development GO:0002064 epithelial cell development GO:0006022 aminoglycan metabolic process GO:0006023 aminoglycan biosynthetic process GO:0006024 glycosaminoglycan biosynthetic process GO:0006026 aminoglycan catabolic process GO:0006027 glycosaminoglycan catabolic process GO:0006720 isoprenoid metabolic process GO:0006721 terpenoid metabolic process GO:0006887 exocytosis GO:0006979 response to oxidative stress GO:0007548 sex differentiation GO:0008406 gonad development GO:0008584 male gonad development GO:0009636 response to toxic substance GO:0010035 response to inorganic substance GO:0010038 response to metal ion GO:0014074 response to purine-containing compound GO:0016050 vesicle organization GO:0016055 Wnt signaling pathway GO:0016101 diterpenoid metabolic process GO:0017157 regulation of exocytosis GO:0030203 glycosaminoglycan metabolic process GO:0031960 response to corticosteroid GO:0042157 lipoprotein metabolic process GO:0042476 odontogenesis GO:0042542 response to hydrogen peroxide GO:0042692 muscle cell differentiation GO:0044089 positive regulation of cellular component biogenesis GO:0045137 development of primary sexual characteristics GO:0045445 myoblast differentiation GO:0045921 positive regulation of exocytosis GO:0046546 development of primary male sexual characteristics GO:0046661 male sex differentiation GO:0046683 response to organophosphorus GO:0048545 response to steroid hormone GO:0048608 reproductive structure development GO:0048627 myoblast development GO:0051047 positive regulation of secretion GO:0051146 striated muscle cell differentiation GO:0051384 response to glucocorticoid GO:0051591 response to cAMP GO:0051592 response to calcium ion GO:0055001 muscle cell development GO:0055002 striated muscle cell development GO:0060008 Sertoli cell differentiation GO:0060009 Sertoli cell development GO:0060070 canonical Wnt signaling pathway GO:0060627 regulation of vesicle-mediated transport GO:0061458 reproductive system development GO:0071971 extracellular exosome assembly GO:0072001 renal system development GO:0072073 kidney epithelium development GO:0072163 mesonephric epithelium development GO:0072164 mesonephric tubule development GO:0198738 cell-cell signaling by wnt GO:1901136 carbohydrate derivative catabolic process GO:1901565 organonitrogen compound catabolic process GO:1902115 regulation of organelle assembly GO:1902117 positive regulation of organelle assembly GO:1903532 positive regulation of secretion by cell GO:1903541 regulation of exosomal secretion GO:1903543 positive regulation of exosomal secretion GO:1903551 regulation of extracellular exosome assembly GO:1903553 positive regulation of extracellular exosome assembly GO:1990182 exosomal secretion
Molecular Function	GO:0001948 glycoprotein binding GO:0008022 protein C-terminus binding
Cellular Component	GO:0005775 vacuolar lumen GO:0005796 Golgi lumen GO:0005924 cell-substrate adherens junction GO:0005925 focal adhesion GO:0009897 external side of plasma membrane GO:0030055 cell-substrate junction GO:0043202 lysosomal lumen GO:0098552 side of membrane

> KEGG and Reactome Pathway [ TOP ]
KEGG	hsa04512 ECM-receptor interaction hsa04514 Cell adhesion molecules (CAMs)
Reactome	R-HSA-1971475: A tetrasaccharide linker sequence is required for GAG synthesis R-HSA-202733: Cell surface interactions at the vascular wall R-HSA-1793185: Chondroitin sulfate/dermatan sulfate metabolism R-HSA-4420332: Defective B3GALT6 causes EDSP2 and SEMDJL1 R-HSA-3560801: Defective B3GAT3 causes JDSSDHD R-HSA-3560783: Defective B4GALT7 causes EDS, progeroid type R-HSA-3656253: Defective EXT1 causes exostoses 1, TRPS2 and CHDS R-HSA-3656237: Defective EXT2 causes exostoses 2 R-HSA-1643685: Disease R-HSA-3560782: Diseases associated with glycosaminoglycan metabolism R-HSA-3781865: Diseases of glycosylation R-HSA-1474244: Extracellular matrix organization R-HSA-1630316: Glycosaminoglycan metabolism R-HSA-2022928: HS-GAG biosynthesis R-HSA-2024096: HS-GAG degradation R-HSA-109582: Hemostasis R-HSA-1638091: Heparan sulfate/heparin (HS-GAG) metabolism R-HSA-1430728: Metabolism R-HSA-71387: Metabolism of carbohydrates R-HSA-6806667: Metabolism of fat-soluble vitamins R-HSA-196854: Metabolism of vitamins and cofactors R-HSA-3000171: Non-integrin membrane-ECM interactions R-HSA-975634: Retinoid metabolism and transport R-HSA-162582: Signal Transduction R-HSA-3000170: Syndecan interactions R-HSA-2187338: Visual phototransduction

> KEGG and Reactome Pathway

[ TOP ]

KEGG

hsa04512 ECM-receptor interaction
hsa04514 Cell adhesion molecules (CAMs)

Reactome

R-HSA-1971475: A tetrasaccharide linker sequence is required for GAG synthesis
R-HSA-202733: Cell surface interactions at the vascular wall
R-HSA-1793185: Chondroitin sulfate/dermatan sulfate metabolism
R-HSA-4420332: Defective B3GALT6 causes EDSP2 and SEMDJL1
R-HSA-3560801: Defective B3GAT3 causes JDSSDHD
R-HSA-3560783: Defective B4GALT7 causes EDS, progeroid type
R-HSA-3656253: Defective EXT1 causes exostoses 1, TRPS2 and CHDS
R-HSA-3656237: Defective EXT2 causes exostoses 2
R-HSA-1643685: Disease
R-HSA-3560782: Diseases associated with glycosaminoglycan metabolism
R-HSA-3781865: Diseases of glycosylation
R-HSA-1474244: Extracellular matrix organization
R-HSA-1630316: Glycosaminoglycan metabolism
R-HSA-2022928: HS-GAG biosynthesis
R-HSA-2024096: HS-GAG degradation
R-HSA-109582: Hemostasis
R-HSA-1638091: Heparan sulfate/heparin (HS-GAG) metabolism
R-HSA-1430728: Metabolism
R-HSA-71387: Metabolism of carbohydrates
R-HSA-6806667: Metabolism of fat-soluble vitamins
R-HSA-196854: Metabolism of vitamins and cofactors
R-HSA-3000171: Non-integrin membrane-ECM interactions
R-HSA-975634: Retinoid metabolism and transport
R-HSA-162582: Signal Transduction
R-HSA-3000170: Syndecan interactions
R-HSA-2187338: Visual phototransduction

Summary
Symbol	SDC1
Name	syndecan 1
Aliases	CD138; syndecan; SYND1; syndecan proteoglycan 1; SDC; CD138 antigen; heparan sulfate proteoglycan fibroblast ......
Chromosomal Location	2p24.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Literatures that report relations between SDC1 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.

> Text Mining

[ TOP ]

Literatures describing the relation between SDC1 and anti-tumor immunity in human cancer.

PMID	Cancer type	Relation to immunity	Evidence sentences
24388357	Plasma Cell Myeloma	Candidate for immunotherapy target	Transfection of chimeric anti-CD138 gene enhances natural killer cell activation and killing of multiple myeloma cells. However, these retargeted NK-92MI (NK-92MI-scFv) displayed markedly enhanced cytotoxicity against CD138-positive human MM cell lines (RPMI8226, U266 and NCI-H929) and primary MM cells at various effector-to-target ratios (E:T) as compared to the empty vector-transfected NK-92MI (NK-92MI-mock).
16880256	Multiple myeloma(IgA, IgD, IgE, IgM, IgG)	Promote immunity	In this study, we show that the clonogenicity of several human tumor cell lines and primary tumor cells from myeloma patients is enhanced by their interactions with DCs. Myeloma cells cultured in the presence of DCs have an altered phenotype with an increased proportion of cells lacking terminal plasma cell differentiation marker CD138. DC-tumor interaction also leads to the up-regulation of B cell lymphoma 6 expression in myeloma cells. Effects of DCs on myeloma cells are inhibited by blockade of the receptor activator of NF-kB (RANK)-RANK ligand and B cell-activating factor-APRIL (a proliferation-inducing ligand)-mediated interactions.

Summary
Symbol	SDC1
Name	syndecan 1
Aliases	CD138; syndecan; SYND1; syndecan proteoglycan 1; SDC; CD138 antigen; heparan sulfate proteoglycan fibroblast ......
Chromosomal Location	2p24.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.

> High-throughput Screening

[ TOP ]

Statistical results of SDC1 in screening data sets for detecting immune reponses.

PMID	Screening System	Cancer Type	Cell Line	Data Set	Statistical Results	Relation to immunity
29301958	CRISPR-Cas9	melanoma	B16F10	Pmel-1 T cell	NA/NS	NA/NS
29301958	CRISPR-Cas9	melanoma	B16F10	OT-1 T cell	NA/NS	NA/NS
28783722	CRISPR-Cas9	melanoma	Mel624	2CT-CRISPR	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX+Anti-PD1	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX	NA/NS	NA/NS
25691366	RNAi	Breast cancer	MCF7	Luc-CTL assay	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Primary screen	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Secondary screen	NA/NS	NA/NS

Summary
Symbol	SDC1
Name	syndecan 1
Aliases	CD138; syndecan; SYND1; syndecan proteoglycan 1; SDC; CD138 antigen; heparan sulfate proteoglycan fibroblast ......
Chromosomal Location	2p24.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders

> Expression difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the expression difference of SDC1 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	Log2 (Fold Change)	P value
1	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	14	12	-1.107	0.143
2	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	6	5	-1.401	0.52
3	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	7	-0.897	0.605
4	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	-0.089	0.9
5	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	-0.399	0.882
6	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0.295	0.926
7	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	26	23	-0.359	0.579
8	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	15	11	0.147	0.92
9	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	11	12	-1.012	0.552
10	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	4	8	0.31	0.869
11	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	2	0	0	1
12	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	2	8	0.992	0.723
13	29443960	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	68	230	-0.14	0.483

> Mutation difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the mutation difference of SDC1 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	% Mut/Res	% Mut/NRes	% Diff (R vs NR)	Pval
1	25765070	Non-small cell lung cancer (NSCLC)	all	Anti-PD-1 (pembrolizumab)	14	17	0	0	0	1
2	25765070	Non-small cell lung cancer (NSCLC)	smoking	Anti-PD-1 (pembrolizumab)	10	3	0	0	0	1
3	25765070	Non-small cell lung cancer (NSCLC)	non-smoking	Anti-PD-1 (pembrolizumab)	4	14	0	0	0	1
4	26359337	Melanoma	all	Anti-CTLA-4 (ipilimumab)	27	73	3.7	2.7	1	1
5	26359337	Melanoma	BRAFi	Anti-CTLA-4 (ipilimumab)	0	14	0	0	0	1
6	26359337	Melanoma	non-BRAFi	Anti-CTLA-4 (ipilimumab)	27	59	3.7	3.4	0.3	1
7	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	21	17	0	0	0	1
8	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	6	0	0	0	1
9	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	13	11	0	0	0	1
10	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0	0	0	1
11	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0	0	0	1
12	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0	0	0	1
13	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	38	27	0	0	0	1
14	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	22	13	0	0	0	1
15	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	16	14	0	0	0	1
16	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	11	13	0	0	0	1
17	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	6	1	0	0	0	1
18	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	5	12	0	0	0	1

Summary
Symbol	SDC1
Name	syndecan 1
Aliases	CD138; syndecan; SYND1; syndecan proteoglycan 1; SDC; CD138 antigen; heparan sulfate proteoglycan fibroblast ......
Chromosomal Location	2p24.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of SDC1. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.

> Lymphocyte [ TOP ]

Summary
Symbol	SDC1
Name	syndecan 1
Aliases	CD138; syndecan; SYND1; syndecan proteoglycan 1; SDC; CD138 antigen; heparan sulfate proteoglycan fibroblast ......
Chromosomal Location	2p24.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of SDC1. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by SDC1. > Immunoinhibitor > Immunostimulator > MHC molecule

> Immunoinhibitor [ TOP ]

> Immunostimulator [ TOP ]

> MHC molecule [ TOP ]

Summary
Symbol	SDC1
Name	syndecan 1
Aliases	CD138; syndecan; SYND1; syndecan proteoglycan 1; SDC; CD138 antigen; heparan sulfate proteoglycan fibroblast ......
Chromosomal Location	2p24.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of SDC1. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor

> Chemokine [ TOP ]

> Receptor [ TOP ]

Summary
Symbol	SDC1
Name	syndecan 1
Aliases	CD138; syndecan; SYND1; syndecan proteoglycan 1; SDC; CD138 antigen; heparan sulfate proteoglycan fibroblast ......
Chromosomal Location	2p24.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Distribution of SDC1 expression across immune and molecular subtypes. > Immune subtype > Molecular subtype

> Immune subtype [ TOP ]

> Molecular subtype [ TOP ]

Summary
Symbol	SDC1
Name	syndecan 1
Aliases	CD138; syndecan; SYND1; syndecan proteoglycan 1; SDC; CD138 antigen; heparan sulfate proteoglycan fibroblast ......
Chromosomal Location	2p24.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Associations between SDC1 and clinical features. > Overall survival analysis > Cancer stage > Tumor grade

> Overall survival [ TOP ]

> Stage [ TOP ]

> Grade [ TOP ]

Summary
Symbol	SDC1
Name	syndecan 1
Aliases	CD138; syndecan; SYND1; syndecan proteoglycan 1; SDC; CD138 antigen; heparan sulfate proteoglycan fibroblast ......
Chromosomal Location	2p24.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Drugs targeting SDC1 collected from DrugBank database.

> Drugs from DrugBank database [ TOP ]
There is no record.

Browse SDC1